Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
LONDON — Shares of British pharmaceuticals giant GSK plunged 9% Monday, after a U.S. court ruled that scientific evidence could be presented as a stack of lawsuits relating to the discontinued heartburn drug Zantac move forward.